Literature DB >> 15386685

Co-payments for prescription drugs and the demand for doctor visits--evidence from a natural experiment.

Rainer Winkelmann1.   

Abstract

The German health care reform of 1997 provides a natural experiment for evaluating the price sensitivity of demand for physicians' services. As a part of the reform, co-payments for prescription drugs were increased step up to 200%. However, certain groups of people were exempted from the increase, providing a natural control group against which the changed demand for physicians' services of the treated, those subject to increased co-payments, can be assessed. The differences-in-differences estimates indicate that increased co-payments reduced the number of doctor visits by about 10% on an average. 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386685     DOI: 10.1002/hec.868

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

Review 1.  How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011.

Authors:  Astrid Kiil; Kurt Houlberg
Journal:  Eur J Health Econ       Date:  2013-08-29

2.  Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach.

Authors:  Jonas Schreyögg; Markus M Grabka
Journal:  Eur J Health Econ       Date:  2009-09-16

3.  Curing over-use by prescribing fees: an evaluation of the effect of user fees' implementation on healthcare use in the Czech Republic.

Authors:  Lucie Kalousova
Journal:  Health Policy Plan       Date:  2014-04-30       Impact factor: 3.344

4.  Patient cost sharing and physician visits by socioeconomic position: findings in three Western European countries.

Authors:  Lourdes Lostao; Enrique Regidor; Siegfried Geyer; Pierre Aïach
Journal:  J Epidemiol Community Health       Date:  2007-05       Impact factor: 3.710

5.  A systematic review of strategies used for controlling consumer moral hazard in health systems.

Authors:  Zohreh Koohi Rostamkalaee; Mehdi Jafari; Hasan Abolghasem Gorji
Journal:  BMC Health Serv Res       Date:  2022-10-18       Impact factor: 2.908

6.  Resource allocation and purchasing arrangements to improve accessibility of medicines: Evidence from Iran.

Authors:  Peivand Bastani; Gholamhossein Mehralian; Rasoul Dinarvand
Journal:  J Res Pharm Pract       Date:  2015 Jan-Mar

7.  Forgone care and financial burden due to out-of-pocket payments within the German health care system.

Authors:  Patrick Bremer
Journal:  Health Econ Rev       Date:  2014-12-20

8.  Ethical issues in implementation research: a discussion of the problems in achieving informed consent.

Authors:  Jane L Hutton; Martin P Eccles; Jeremy M Grimshaw
Journal:  Implement Sci       Date:  2008-12-17       Impact factor: 7.327

9.  What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Authors:  Marin C Gemmill; Sarah Thomson; Elias Mossialos
Journal:  Int J Equity Health       Date:  2008-05-02

10.  Direct costs of inequalities in health care utilization in Germany 1994 to 2009: a top-down projection.

Authors:  Lars Eric Kroll; Thomas Lampert
Journal:  BMC Health Serv Res       Date:  2013-07-12       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.